Coronavirus Update - 09th November 2020

We would like to reassure our customers that as England enters its second national lockdown period, we remain open for business and at full capacity as we have done since the start of this pandemic and fully comply with all government guidance on minimising the risks of COVID-19.

As the situation continues to evolve, we will keep all our customers and stakeholders informed of our activities through this web-page which is updated on a regular basis.

Our work and case studies

Challenge: A strategy of rapid clinical progression – dose determination to manufacture and to patient administration within 4 days, necessitating a timeline of dose determination to shipping of product to the remote clinical site within 48 hours - repeated for escalating clinical dose levels.


Japanese Big-Pharma Corporation.


Standard manufacturing procedures replaced with project specific procedures, managed through change control, enabling timelines for dose determination/manufacturing order approval to shipment to the clinic to be reduced from 2 -3 weeks to 48 hours. 


Accelerated Manufacturing 48 HRS slide

Accelerated Manufacturing 21 Days slide